Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Poolbeg Pharma PLC (POLBF)
London, GB
Poolbeg Pharma plc operates as a clinical-stage pharmaceutical company, headquartered in London, United Kingdom, with a focus on developing treatments for infectious diseases. Its current product pipeline includes: POLB 001: A p38 MAP Kinase inhibitor being advanced for the treatment of severe influenza. POLB 002: An innovative, first-in-class RNA-based immunotherapy, acquired through a licensing agreement, designed for intranasal administration to combat various respiratory viral infections. POLB 003: An intramuscular vaccine aimed at preventing Melioidosis. Beyond specific drug candidates, Poolbeg Pharma holds licensed access to advanced micro- and nanoencapsulation technology. This technology is being leveraged to develop an oral vaccine delivery platform capable of transporting immune-stimulating antigens to specific areas of the gut. The company also utilizes an artificial intelligence-powered program to aid in drug discovery. Furthermore, Poolbeg Pharma is developing a biomarker platform with the goal of identifying individuals at risk of progressing to severe disease. It also operates a sophisticated, model-derived vaccine discovery platform dedicated to uncovering novel vaccine candidates. The company was incorporated in 2021.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +40.71% | +40.71% | +40.71% | -49.32% | -48.00% | -35.35% | -35.35% | -35.35% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+19.0% Q4'25: -16.3% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-722.8% Q4'25: -1,727.0% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+20.5% Q4'25: +40.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q4'23)
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
| EBITDA |
-6.00M
|
-6.42M
|
—
— – —
|
| EBIT |
-6.11M
|
-6.42M
|
—
— – —
|
| Net Income |
-5.79M
est: -6.25M (+7.3%)
|
-5.69M
est: -4.35M (-30.9%)
|
-3.99M
-3.99M – -3.99M
+8.2% YoY
|
| SGA |
5.26M
|
4.83M
|
—
— – —
|
| EPS |
-0.01
est: -0.01 (+7.2%)
|
-0.01
est: -0.01 (-8.1%)
|
-0.01
-0.01 – -0.01
+8.2% YoY
|
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jeremy Skillington | Chief Executive Officer & Director | 413.8K | — |
| Ian O'Connell | Chief Financial Officer & Director | 257.8K | male |
| Cathal Martin Friel | Executive Chairman of The Board | 189.0K | male |
| Carol Dalton | Vice President of Investor Relations & Public Relations | — | — |
| Liam Tremble | Principal Scientist | — | male |
| Ross Crockett | Group Financial Controller | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for POLBF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
